和风支气管内瓣膜可改善异质性肺气肿患者的FEV1和生活质量

Q4 Medicine

Clinical Pulmonary Medicine Pub Date : 2019-03-01 DOI:10.1097/CPM.0000000000000303

Christopher Mcgrath, F. West, D. Zappetti

{"title":"和风支气管内瓣膜可改善异质性肺气肿患者的FEV1和生活质量","authors":"Christopher Mcgrath, F. West, D. Zappetti","doi":"10.1097/CPM.0000000000000303","DOIUrl":null,"url":null,"abstract":"reach peak benefit by week 12. However, subgroup analysis shows that this drug is primarily effective in patients with increased baseline eosinophil count or increased fraction of exhaled nitric oxide, and performs no differently than matched volume placebo in patients who do not have these proxies of type-2 inflammation; therefore, thoughtful consideration of patient candidacy is still necessary when using dupilumab as a treatment adjunct. Dupilumab is a welcome addition to a growing armamentarium against asthma mediated by type-2 inflammation, with a novel mechanism that targets both IL-4 and IL-13.","PeriodicalId":10393,"journal":{"name":"Clinical Pulmonary Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/CPM.0000000000000303","citationCount":"0","resultStr":"{\"title\":\"Zephyr Endobronchial Valves Improve FEV1 and Quality of Life in Heterogenous Emphysema\",\"authors\":\"Christopher Mcgrath, F. West, D. Zappetti\",\"doi\":\"10.1097/CPM.0000000000000303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"reach peak benefit by week 12. However, subgroup analysis shows that this drug is primarily effective in patients with increased baseline eosinophil count or increased fraction of exhaled nitric oxide, and performs no differently than matched volume placebo in patients who do not have these proxies of type-2 inflammation; therefore, thoughtful consideration of patient candidacy is still necessary when using dupilumab as a treatment adjunct. Dupilumab is a welcome addition to a growing armamentarium against asthma mediated by type-2 inflammation, with a novel mechanism that targets both IL-4 and IL-13.\",\"PeriodicalId\":10393,\"journal\":{\"name\":\"Clinical Pulmonary Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/CPM.0000000000000303\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CPM.0000000000000303\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CPM.0000000000000303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

在第12周达到最大收益。然而，亚组分析显示，该药物主要对基线嗜酸性粒细胞计数增加或呼出一氧化氮分数增加的患者有效，并且在没有这些2型炎症指标的患者中与匹配容量安慰剂的效果没有区别;因此，在使用杜匹单抗作为辅助治疗时，对患者的候选性进行深思熟虑的考虑仍然是必要的。Dupilumab是抗由2型炎症介导的哮喘的一个受欢迎的补充，具有针对IL-4和IL-13的新机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Zephyr Endobronchial Valves Improve FEV1 and Quality of Life in Heterogenous Emphysema

reach peak benefit by week 12. However, subgroup analysis shows that this drug is primarily effective in patients with increased baseline eosinophil count or increased fraction of exhaled nitric oxide, and performs no differently than matched volume placebo in patients who do not have these proxies of type-2 inflammation; therefore, thoughtful consideration of patient candidacy is still necessary when using dupilumab as a treatment adjunct. Dupilumab is a welcome addition to a growing armamentarium against asthma mediated by type-2 inflammation, with a novel mechanism that targets both IL-4 and IL-13.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Pulmonary Medicine Medicine-Critical Care and Intensive Care Medicine

自引率

0.00%

发文量

期刊介绍： Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.